Literature DB >> 9638636

Lung cancer: therapeutic modalities and cytoprotection.

J H Schiller1.   

Abstract

Lung cancer is the leading cancer killer in the United States today. The current methods of treatment, radiation and various chemotherapies, have been used with some success; however, early detection remains the key to successful therapy. Current clinical trials indicate that an improvement of available therapies is needed. Consequently, the development of new approaches to treatment is foremost in the minds of researchers. Advances in molecular medicine have produced new drugs that can protect normal cells from chemotherapy-induced toxicities, resulting in enhanced drug delivery with few dose reductions. This review will discuss some of the advances that have been made in understanding the molecular biology of lung cancer as well as the current and most promising methods of treatment used for various forms of lung cancer. The potential contribution of cytoprotectors to enhance the safety and effectiveness of these therapies will be examined.

Entities:  

Mesh:

Year:  1998        PMID: 9638636     DOI: 10.1007/pl00007599

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  2 in total

1.  Adhesion molecules affected by treatment of lung cancer cells with epidermal growth factor.

Authors:  Fernando L A Fonseca; Ligia A Azzalis; David Feder; Everson Nogoceke; Virginia B C Junqueira; Vitor E Valenti; Luiz Carlos de Abreu
Journal:  Lung       Date:  2011-06-09       Impact factor: 2.584

2.  Cysteine proteinase cathepsin H in tumours and sera of lung cancer patients: relation to prognosis and cigarette smoking.

Authors:  A Schweiger; A Staib; B Werle; M Krasovec; T T Lah; W Ebert; V Turk; J Kos
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.